Regulation - Pricing

Filter

Current filters:

Pricing

Popular Filters

201 to 225 of 321 results

UK's NICE delays decision on Roche's Zelboraf, asking for more information

10-08-2012

UK health care watchdog the National Institute for Health and Clinical Excellence (NICE) today (August…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

NICE rejects Alimera's Iluvien for DMO in draft guidance

08-08-2012

In draft guidance published today (August 8) by UK drugs watchdog the National Institute for Health and…

Alimera SciencesEuropeIluvienOphthalmicsPharmaceuticalPricingRegulation

UK NICE draft guidance backs Servier's Procoralan for chronic heart failure

06-08-2012

The UK's drugs watchdog the National Institute for Health and Clinical Excellence (NICE), in draft guidance…

Cardio-vascularEuropePharmaceuticalPricingProcoralanRegulationServier

UK's NICE to takeover role of assessing high-cost rare disease drugs

25-07-2012

In the UK, the role of assessing very high cost drugs for people who suffer with rare conditions, under…

BiotechnologyEuropePharmaceuticalPricingRare diseasesRegulation

UK NICE says final "yes" for Bayer's Xarelto to treat blood clots

24-07-2012

Confirming its final draft guidance last month (The Pharma Letter June 1), in final guidance published…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

J&J'S rilpivirine also proven for combination HIV product, says IQWiG

13-07-2012

Since the start of 2012, a new drug - rilpivirine from US health care giant Johnson & Johnson (NYSE:…

Anti-viralsEuropeEvipleraJohnson & JohnsonPharmaceuticalPricingRegulationrilpivirine

US patients get faster access to more cancer drugs than Europeans, says Tufts

11-07-2012

Cancer patients in the USA get faster access to more oncology drugs to treat their disease than patients…

BiotechnologyEuropeHealthcareNorth AmericaOncologyPharmaceuticalPricingRegulation

Australia's health care regulations struggle to keep up with population aging

10-07-2012

The growing elderly population and its associated disease burden add to the economic challenges faced…

Asia-PacificHealthcareMarkets & MarketingPharmaceuticalPricingRegulation

NICE draft guidance continues negative on Roche's Avastin for metastatic breast cancer

06-07-2012

Final draft guidance published today (July 6) by the UK's drugs watchdog the National Institute for Health…

AvastinEuropeOncologyPharmaceuticalPricingRegulationRoche

New Zealand agrees to fund Iressa but amends Tarceva use

05-07-2012

New Zealand's pharmaceutical management agency PHARMAC has approved the proposal to fund AstraZeneca's…

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

Germany's IQWiG finds no proof of added benefit for AstraZeneca's Caprelsa in thyroid cancer

05-07-2012

The German Institute for Quality and Efficiency in Health Care (IQWiG) has now examined the added benefit…

AstraZenecaCaprelsaEuropeOncologyPharmaceuticalPricingRegulation

Gilead files elvitegravir and cobicistat with FDA; AHF plea on Quad pricing

29-06-2012

US biotech firm Gilead Sciences (Nasdaq: GILD), world's largest maker of HIV drugs, has submitted a New…

Anti-viralsBiotechnologycobicistatelvitegravirGilead SciencesNorth AmericaPricingQuadRegulation

Australian patients to benefit from new PBS listings; OTC reforms

26-06-2012

The listing of 11 prescription medicines on the Australian Pharmaceutical Benefits Scheme (PBS) has been…

Asia-PacificBiotechnologyHealthcarePharmaceuticalPricingRegulation

Issues to be navigated to unleash full potential of stem cell therapies

18-06-2012

Pharmaceutical, biotech and medical device companies are showing increased interest in stem cell research…

BiotechnologyPharmaceuticalPricingRegulationResearch

European generics trade group urges addressing medicines affordability and availability risks

17-06-2012

With pensioners set to represent over 60% of the working population by 2060 in Europe, the pharmaceutical…

EuropeGenericsHealthcarePricingRegulation

UK's NICE denies NHS access to Roche melanoma drug Zelboraf

15-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) has issued draft guidance…

EuropeOncologyPharmaceuticalPricingRegulationRocheZelboraf

Australia's PIC reports to Ministers on treatment and reimbursement of similar biologics

14-06-2012

The Australian Pharmaceuticals Industry Council (PIC), with industry group members AusBiotech, Medicines…

Asia-PacificBiotechnologyGenericsPharmaceuticalPricingRegulation

UK's NICE takes second look at Amgen's Xgeva

12-06-2012

UK drugs watchdog the National Institute for Health and Clinical Excellence (NICE) today launched a second…

AmgenBiotechnologyEuropeOncologyPricingRegulationXgeva

German model for assessment of new medicines slammed by EU pharma leaders

11-06-2012

Leading pharmaceutical companies in Europe, represented in the European Federation of Pharmaceutical…

BiotechnologyEuropePharmaceuticalPoliticsPricingRegulation

NZ's PHARMAC consults on funding for Iressa and Tarceva

31-05-2012

The Pharmaceutical Management Agency of New Zealand, PHARMAC, is seeking feedback on a proposal to:

Asia-PacificAstraZenecaIressaOncologyPharmaceuticalPricingRegulationRocheTarceva

"NICE" news for Bayer, as UK watchdog backs Xarelto for AF

23-05-2012

There was good news today (May 23) for German drug major Bayer (BAYN: DE), when the UK's drug watchdog,…

BayerCardio-vascularEuropePharmaceuticalPricingRegulationXarelto

201 to 225 of 321 results

Back to top